YMI is, as the name would suggest, a biotech stock. It's developing a handful of cancer therapies, though its flagship drug is CYT387, for treating myelofibrosis. It's in Phase 2 trials right now. While YM BioSciences may be at least a couple of years away from getting any of its R&D projects approved, banks, brokerage, and research firms have made no bones about their love and hope for the stock. That bullish banter alone could be enough to light a fire under the stock again, and erase last year's tumble from a price of more than $3.00. The spring sure looks coiled anyway.
All my posts are my OPINION>>IMO>>>Do your own Due Diligence!!.......rareF...deal with it
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM